Cargando…
Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity
Rapamycin, a specific inhibitor for mTOR complex 1, is an FDA-approved immunosuppressant for organ transplant. Recent developments have raised the prospect of using rapamycin to treat cancer or diabetes and to delay aging. It is therefore important to assess how rapamycin treatment affects glucose h...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer-Verlag
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3354320/ https://www.ncbi.nlm.nih.gov/pubmed/22105852 http://dx.doi.org/10.1007/s00109-011-0834-3 |